Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exploiting Autophagy to Kill Cancer Cells

This article was originally published in Start Up

Executive Summary

Scientists at Stanford have identified a compound that kills most kidney cancer cells without disturbing normal tissue. A new weapon against renal cell carcinoma would be welcome enough. But this research and other recent findings are pointing to how the emerging understanding of autophagy, a natural regulatory process in cells, may be useful in the design of new therapies in cancer and also, potentially, neurodegenerative and immunologic diseases.
Advertisement

Related Content

Cancer Metabolism Approach Uncovers Drug Target, Biomarker
For Cancer Therapy, Radiation Protection and Delayed Tumor Growth from the Same Mechanism
Teasing Out Mechanisms of Small-Molecule Kinase Inhibition
The A-List: 2008's Trend Shaping Series A Financings
The A-List: 2008's Trend Shaping Series A Financings
Targeted Cancer Drugs
Nothing Random About It: The State of Cancer Drug Development at FDA

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel